Entries by oslocancer

Receives Prestigious Grant for a Second Time

Professor Harald Stenmark is granted the European Research Council’s (ERC) Advanced Grant for his cancer research. This is the second time he receives the grant; a privilege that has only befallen two other people, professor Edvard Moser (NTNU) and professor Kenneth Hugdahl (UiB). Through the grant Stenmark’s research project “Coincidence detection of proteins and lipids […]

Bekjemper kreft med gentilpasset behandling

Gentilpasset behandling har siden begynnelsen av 2000-tallet blitt beskrevet som et av de nye, viktige våpnene som kan bekjempe kreft. Hør forsker Hege G. Russnes og professor Anne Hansen Ree, her fra Cancer Crosllinks i januar i år, fortelle om deres forskningsprosjekt MetAction, og hvordan de tar i bruk gentilpasset behandling for å gi et […]

Photocure Expansion Accepted by FDA

Oslo Cancer Cluster member Photocure recently announced that the U.S. Food and Drug Administration (FDA) has accepted an expansion of the bladder cancer detection system “Cysview”. The FDA has accepted a supplemental New Drug Application (NDA) for “Cysview”. Photocure, the Norwegian company behind the drug-device system, has now been allowed to expand the system to […]

Welcome to Our New Members

Entering 2018, Oslo Cancer Cluster welcomes four new members to the fold. Cellmover, Bryn Aarflot, Kuehne + Nagel and Mercuri Urval are our new cluster members.   The Importance of Getting There Founded in 1890, Kuehne + Nagel operates from 9 locations in Norway, offering tailored logistics solutions for different industries, including for healthcare and […]

Need Money For Your Life Science Start-up?

Inven2 are distributing start-up funds in Life Science! Very good news for Biotechs and cancer research companies in their early stages of development.   Attention all Oslo Cancer Cluster and Incubator members.  Inven2 received in late December 5 million NOK from Innovation Norway. They are now, subsequently, handing them out to Life science start-ups. Inven2 […]

10th Cancer Crosslinks: Precision Treatment Reviewed

For the tenth time the cancer experts gathered to share knowledge and ideas at Oslo Cancer Cluster Innovation Park. Cancer Crosslinks 2018 presented a diverse program covering themes from immuno-oncology to cachexia, to big data.   Cancer research is changing rapidly. Immunotherapy and precision medicine has revolutionized cancer treatment. This year’s Cancer Crosslinks took a […]

Follow the 10th Cancer Crosslinks: Stream and Program

Thursday January the 18th it’s time for the 10th Cancer Crosslinks here at Oslo Cancer Cluster Innovation Park. Hospital personnel, researchers and everybody interested get together for an update on – and to discuss – the latest within cancer research.   This year’s conference will focus on Precision Treatment in cancer research with the headline: […]

Curida Takover Secures Norwegian Production

To secure Norwegian pharmaceutical production, Oslo Cancer Cluster- member Curida has completed a takeover of Ås produksjonslab AS.   Continued Production at Ås Curida operate in an international marketplace and here the last line of production of pharmaceuticals is mostly taken care of by specialized operators. «Ås produksjonslab» is a company rich in tradition, it […]

Fremtidens kreftbehandling – ta med egne data!

Les kronikken, fra 21.12. 2017 i Aftenposten, om hvordan vi bør forme våre nye sykehusbygg av Ketil Widerberg. Den nye klinikken på Radiumhospitalet må ta helsedatarevolusjonen på alvor. Radiumhospitalet ved Oslo universitetssykehus får nytt klinikkbygg. En god nyhet for kreftpasienter, som blir enda bedre hvis pasientene selv får bidra med data om egen helse. Et […]

Breakthrough Agreement for Phoenix Solutions

A new exciting collaboration among two Oslo Cancer Cluster members has been initiated. GE Healthcare has agreed to be the manufacturer of the target drug delivery platform ACT, made by Phoenix Solutions. Early Christmas Present As an early Christmas present to each other the two companies announced that they had signed an agreement securing manufacturing […]

Oncoinvent With New Lab and Bright Future

The cancer research company and Oslo Cancer Cluster-member Oncoinvent opened this Thursday a brand-new lab and research facilities at Nydalen Oslo. Now they control the whole production line and continue their development of their lead product candidate Radspherin. A Good Year 2017 has been a good year for Oncoinvent. The company has now relocated and […]

Four Cluster Companies Get Innovation Reward

Nacamed, Phoenix Soulutions, NorGenoTech and Clever Health are awarded Innovasjonsrammen for good early-stage innovation and collaboration. Innovasjonsrammen is awarded by Oslo Cancer Cluster with money from Innovation Norway. Congratulations! Important with early financing Early financing while companies are establishing their business is often limited, but can be crucial to get important projects off the ground. […]

Precision Medicine has a New Target

Researchers at the Centre for Cancer Biomedicine, a Center of Excellence and a member of Oslo Cancer Cluster, have discovered an enzyme wreaking havoc inside cells that turns into tumors. For our body to work as normal, cells need to know which way is up. When cells lose track of their orientation, they can start […]

Raising Prostate Cancer Awareness

This week on Monday, Prostate Cancer Day, the Norwegian Cancer Society initiated their Blue-Ribbon Campaign to raise prostate cancer awareness. In line with the campaign, Oslo Cancer Cluster gives you the chance to update yourselves on prostate cancer research Thursday the 30th of November.   The Blue-Ribbon campaign is initially a month’s focus on prostate […]

New Funds for Ultimovacs

Investors are recognizing the huge potential of Oslo Cancer Cluster member Ultimovacs. They are currently investing an additional 125 million NOK in the cancer research company.   Well known investors and Ultimovacs backers Stein Erik Hagen, Anders Wilhelmsen og Bjørn Rune Gjelsten are among financiers putting fresh money into the cancer research company, according to […]

Photocure with FDA Priority

Oslo Cancer Cluster member Photucure recently announced that the U.S. Food and Drug Administration (FDA) has accepted a Priority Review for an expansion of Cysview.   The FDA has accepted a supplemental New Drug Application (NDA) for Cysview on a priority review basis. Photocure, the Oslo, Norway-based company that developed and is marketing the drug-device […]

KUR: En reise langs det elektromagnetiske spekteret

I kursserien Kompetanseutvikling i realfag (KUR), spør vi denne gangen: Er det farlig med stråling? Hvordan påvirkes vi av trådløse nettverk?  Hvordan behandler man kreft med ioniserende stråling? Stråling er en del av hverdagen vår på mange måter.  Det elektromagnetiske spekteret er også en gjenganger i mange læreplaner, både grunnskolen og i videregående skole.  Denne kurskvelden har […]

Roche Medicine Ready to Fight Breast Cancer

On the 15th of August, drug Kadycla (trastuzumab emtansin) is finally approved by the Beslutningsforum and ready to help hundreds with breast cancer in Norway. The drug, developed by company Roche, specifically targets patients with the variant HER2 positive breast cancer – a breast cancer that tests positive for human epidermal growth factor receptor 2, […]

Nominated as “Norway’s smartest industrial company”

Thermo Fisher Scientific is one of three finalists to win the award and title in Oslo this Tuesday. The technology which the biotech company is nominated for, is development of faster and cheaper DNA-sequencing. More than 70 companies were candidates for this year’s price, according to the Norwegian online tech magazine Teknisk Ukeblad.  Thermo Fisher Scientific is one […]

Kronikk i Aftenposten: De nordiske landene kan gjøre noe resten av verden drømmer om

De nordiske landene bør samarbeide mer for å utvikle bedre kreftbehandlinger. Sammen kan Norden bli et globalt forsknings- og testsenter for nye kreftbehandlinger og -medisiner. Det kan gi store gevinster for kreftpasienter i hele verden. Denne kronikken sto på trykk i Aftenposten torsdag 9. mars. Ketil Widerberg, daglig leder i Oslo Cancer Cluster, skrev kronikken samme uke som The Economist, Forskningsrådet og […]

Targovax to present at upcoming conferences

Oslo, Norway, 6 March 2017: Targovax ASA (“Targovax” or “the Company”; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target, primarily, treatment-resistant solid tumors, announces that members of its senior management will present at the following life sciences and investor conferences:
– 10th European Life Science CEO Forum
– Redeye – Fight Cancer Seminar
– 11th Annual BIO-Equity Spring 2017 Conference

Targovax ASA: Fourth quarter and full year 2016 results

Oslo, Norway, 16 February 2017 – Targovax ASA (“Targovax” or “the Company”; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces its fourth quarter and full year 2016 results.

A meeting for investors, analysts and press will take place in Oslo today at 10:00 CET and a conference call will take place at 14.00 CET (details below).

Lytix Biopharma granted 15.9 MNOK from The Research Council of Norway

Lytix Biopharma, a clinical-stage biopharmaceutical company developing novel cancer immune therapies, has been awarded a NOK 15.9 million grant from The Norwegian Research Council (User-driven Research-based Innovation) to support the investigation of LTX-315’s ability to make ’’cold tumors hot’’ and Phase II trial in Triple Negative Breast cancer (TNBC).